ModeX doses first patients in trial of next-gen T-cell engager for aggressive B-cell lymphoma
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
Subscribe To Our Newsletter & Stay Updated